期刊
CANCER LETTERS
卷 438, 期 -, 页码 63-75出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2018.08.030
关键词
Minimal residual disease; Donor lymphocyte infusion; Targeted therapy; Acute leukemia; Myelodysplastic syndrome
类别
资金
- National Natural Science Foundation of China [81530046, 81621001, 81770189]
- Collaborative Innovation Center of Hematology China
- Science and Technology Project of Guangdong Province of China [2016B030230003]
- National Key Research and Development Program of China from the Ministry of Science and Technology [2017YFA0104500]
- project of health collaborative innovation of Guangzhou city [201704020214]
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important curative therapy for patients with leukemia. However, relapse remains the leading cause of death after transplantation. In recent years, substantial progress has been made by Chinese physicians in the field of establishment of novel transplant modality, patient selection, minimal residual disease (MRD) monitoring, and immunological therapies, such as modified donor lymphocyte infusion (DLI) and chimeric antigen receptor T (CART) cells, as well as MRD-directed intervention for relapse. Most of these unique systems are distinct from those in the Western world. In this consensus, we reviewed the efficacy of post-HSCT relapse management practice from available Chinese studies on behalf of the HSCT workgroup of the Chinese Society of Hematology, Chinese Medical Association, and compared these studies with the consensus or guidelines outside China We summarized the consensus on routine practices of post-HSCT relapse management in China and focused on the recommendations of MRD monitoring, risk stratification directed strategies, and modified DLI system. This consensus will likely contribute to the standardization of post-HSCT relapse management in China and become an inspiration for further international cooperation to refine global practices.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据